Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Ifosfamide and Doxorubicin in Advanced Sarcoma
NCT00002526Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 1993
- Primary completion
- Sep 1995
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide and doxorubicin in soft tissue sarcoma (STS) and gynecologic sarcoma, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Objective Response Rate. Started Jan 1993; status: completed.
02
Drugs
ifosfamidedoxorubicin
03
Conditions
soft tissue sarcoma (STS)gynecologic sarcoma
Beyond the preview
Go deeper on NCT00002526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002526.